Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Takeda"

16:01 EDT 24th April 2014 | BioPortfolio

Original Source: Takeda Pharmaceutical Company Limited

1781 Founding Over two centuries ago in 1781, 32-year-old Chobei Takeda I started a business selling traditional Japanese and Chinese medicines in Doshomachi, Osaka, the center of the medicine trade in Japan. His small shop bought medicines from wholesalers, then divided them into smaller batches and sold them to local medicine merchants and doctors. This was the beginning of the present-day Takeda Chemical Industries, Ltd.

Matching Channels

Pertussis Vaccine acellular Takeda

Actos

Actos, produced by Takeda Pharmaceuticals North America, Inc netted $2.5m in sales in 2009, the 9th highest in the world. Actos is a type of thiazolidinediones, acting to increase sensitivity to I...

Prevacid

Prevacid, produced by Takeda Pharmaceuticals North America, Inc netted $2.5 in sales in 2009, the 10th highest in the world. Prevacid, the trade name for lansoprazole, is a proton pump inhibitor d...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Matching News

Takeda Ends Development of Diabetes Drug

Takeda Announces Termination of Fasiglifam (TAK-875) Development OSAKA, Japan, December 26, 2013--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) announced today that it has decided vo...

New Takeda CFO Takes Takeda Investor Search Abroad As Firm Goes Global

The recent influx of foreign executives at Takeda Pharmaceutical has led to a broadening of the firm's shareholder base to beyond its shores.

Takeda Submits a New Drug Application for TAK-438 in Japan for the Treatment of Acid-related Diseases

Osaka, Japan, February 28, 2014 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has submitted a New Drug Application to the Ministry of Health, Labour and Welf...

Takeda Continues Its Diversification By Hiring French COO From GlaxoSmithKline

GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a...

BRIEF-FDA panel backs Takeda drug for ulcerative colitis, Crohn's disease

Dec 9 (Reuters) - Takeda Pharmaceutical Co Ltd : * FDA advisory panel votes 12-9 that available data for Takeda Pharmaceutical

Takeda Continues Diversification By Hiring French COO From GSK

GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a...

Takeda Submits NDA for TAK-438 in Japan

Takeda Pharmaceutical Co. Ltd. announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labor and Welfare for TAK-438 (generic name: Vonoprazan Fumarate).

Takeda Well-Being Program 2013 - "Giving Children in Long-term Treatment the Energy to Live"

Osaka, Japan, February 27, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that the annual programs for the “Takeda Well-Being Program” have been...

Matching PubMed Articles

Vortioxetine for the treatment of major depression.

Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of maj...

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 201...

Nucleophilic cross-linked, dextran coated iron oxide nanoparticles as basis for molecular imaging: synthesis, characterization, visualization and comparison with previous product.

We present a new synthesis protocol for a multivalent, multimodality, nucleophilic nanoparticle ideal for in vivo imaging. Stability requirements necessitated covalent cross-linking of the carbohydrat...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement